8月20日，三鑫医疗今日收盘10.46元，下跌5.42%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到23.13倍，总市值54.64亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.32倍，行业中值39.97倍，三鑫医疗排 名第47位。 资金流向方面，8月20日，三鑫医疗主力资金净流出6142.59万元，近5日总体呈流出状态，5日共流出 6556.40万元。 江西三鑫医疗科技股份有限公司的主营业务是医疗器械研发、制造、销售和服务。公司的主要产品是血 液净化类、给药器具类、心胸外科类、其他类。公司荣获"国家工信部智能制造优秀场景""江西省智能 制造标杆企业""江西省先进级智能工厂""5G+工业互联网"应用示范项目等荣誉，在智能制造和数字化 转型领域获权威认可。 最新一期业绩显示，2025年半年报，公司实现营业收入7.61亿元，同比10.83%；净利润1.15亿元，同比 8.35%，销售毛利率34.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三鑫医疗23.1324.034.0654.64亿行业平均 59.3254.705.08121.09亿行业中值39.9 ...

8月15日，三鑫医疗今日收盘10.01元，上涨1.21%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到22.13倍，总市值52.29亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，三鑫医疗排 名第48位。 资金流向方面，8月15日，三鑫医疗主力资金净流出835.79万元，近5日总体呈流出状态，5日共流出 2621.38万元。 江西三鑫医疗科技股份有限公司的主营业务是医疗器械研发、制造、销售和服务。公司的主要产品是血 液净化类、给药器具类、心胸外科类、其他类。公司荣获"国家工信部智能制造优秀场景""江西省智能 制造标杆企业""江西省先进级智能工厂""5G+工业互联网"应用示范项目等荣誉，在智能制造和数字化 转型领域获权威认可。 最新一期业绩显示，2025年半年报，公司实现营业收入7.61亿元，同比10.83%；净利润1.15亿元，同比 8.35%，销售毛利率34.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三鑫医疗22.1323.003.8852.29亿行业平均 56.5852.305.00119.53亿行业中值39.97 ...

8月12日，三鑫医疗今日收盘10.75元，上涨14.24%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到23.77倍，创738天以来新低，总市值56.16亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均57.51倍，行业中值41.25倍，三鑫医疗排 名第49位。 资金流向方面，8月12日，三鑫医疗主力资金净流出72.59万元，近5日总体呈流入状态，5日共流入 1490.98万元。 江西三鑫医疗科技股份有限公司的主营业务是医疗器械研发、制造、销售和服务。公司的主要产品是血 液净化类、给药器具类、心胸外科类、其他类。公司荣获"国家工信部智能制造优秀场景""江西省智能 制造标杆企业""江西省先进级智能工厂""5G+工业互联网"应用示范项目等荣誉，在智能制造和数字化 转型领域获权威认可。 最新一期业绩显示，2025年半年报，公司实现营业收入7.61亿元，同比10.83%；净利润1.15亿元，同比 8.35%，销售毛利率34.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三鑫医疗23.7724.704.1756.16亿行业平均 57.5153.344.97120.28 ...

Company Overview - Sanxin Medical focuses on the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery devices, and cardiothoracic surgical products [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] Financial Performance - In Q1 2025, Sanxin Medical reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The company's gross profit margin stands at 34.62% [2] Market Position - As of August 1, Sanxin Medical's stock closed at 8.98 yuan, with a rolling PE ratio of 20.62, marking a 553-day low, and a total market capitalization of 4.691 billion yuan [1] - The average PE ratio for the medical device industry is 53.65, with a median of 37.22, placing Sanxin Medical at the 45th position within the industry [1][3] Shareholder Information - As of March 31, 2025, Sanxin Medical has 18,367 shareholders, an increase of 1,327 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Company Overview - Jiangxi Sanxin Medical Technology Co., Ltd. specializes in the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery devices, and cardiothoracic surgical instruments [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] - The company has been recognized as a "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration of China [2] Financial Performance - In the first quarter of 2025, the company reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The gross profit margin for the same period was 34.62% [2] Market Position - As of May 28, the company's stock closed at 8.19 yuan, up 4.20%, with a rolling price-to-earnings (PE) ratio of 18.81, marking a new low in 46 days [1] - The average PE ratio for the medical device industry is 48.81, with a median of 35.46, placing Sanxin Medical at the 44th position in the industry ranking [1][3] - The total market capitalization of the company is 4.278 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 18,367, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]